Immune checkpoint inhibitors, especially programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors have made a breakthrough in the treatment of NSCLC and changed the treatment patern for NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.